Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotechnology, comments on the issuance of Patent No. 7783866 by the Japan Patent Office for PDS0101 granting broad composition of matter and methods of use claims: https://t.co/OnpR0KzKhh $PDSB

PDS Biotech announced the Japan Patent Office has granted a patent for PDS0101 covering broad composition claims. Together with anticipated biologics exclusivity in the U.S., the Company has patent & market protections for PDS0101 into the 2040s. https://t.co/OnpR0KzKhh $PDSB

President and CEO of PDS Biotech, Frank Bedu-Addo, PhD, comments on the Company's upcoming Type C Meeting with the FDA to pursue a potential accelerated approval pathway for PDS0101: https://t.co/h1o95J629v

PDS Biotech will discuss a proposed amendment to its Ph.3 VERSATILE-003 trial in an upcoming meeting with the FDA. The amendment could enable a potential accelerated approval pathway for PDS0101 in HPV16-positive R/M head and neck cancer. https://t.co/h1o95J629v $PDSB

PDS Biotech today announced that its request for a Type C Meeting with the FDA has been accepted by the agency, and the meeting has been scheduled to occur this month. For more details: https://t.co/h1o95J629v $PDSB

During the third quarter PDS Biotech announced the completion of VERSATILE-002 Phase 2 trial with results leading the Company to seek an accelerated approval pathway in the ongoing VERSATILE-003 Phase 3 trial design. See the clinical & corporate update: https://t.co/D2deQgJ7Pe

Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, comments on the Company's plan to seek accelerated approval pathway in the VERSATILE-003 Phase 3 trial. For more info, visit: https://t.co/D2deQgJ7Pe $PDSB

PDS Biotech today provided a business and clinical update and reported financial results for the third quarter ended September 30, 2025. See it here: https://t.co/D2deQgJ7Pe $PDSB

PDS Biotech will host a conference call to report financial results for the quarter ended September 30, 2025 and provide a clinical programs update tomorrow, November 13th, at 8:00 AM ET. Join the live webcast here: https://t.co/YMSjl52xrj $PDSB

PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering: https://t.co/rApcDJe5gW $PDSB

New data shows that PDS01ADC promotes stem cell-like killer T cells and memory T cells that self-replicate and are therefore capable of potent and long-lasting anti-tumor activity. Read more on the data presented at #SITC25: https://t.co/8kFQ7iiMtV $PDSB

Frank Bedu-Addo, Ph.D., President and Chief Executive Officer of PDS Biotech, comments on the positive clinical and translational data presented at the 2025 Society for Immunotherapy of Cancer Annual Meeting: https://t.co/8kFQ7iiMtV #SITC25 $PDSB

Recently presented data at #SITC25 shows that PDS Biotech's novel investigational immunocytokine, PDS01ADC, reprograms natural killer (NK) cells to possess characteristics that make them more active in killing cancer cells. Read more: https://t.co/8kFQ7iiMtV $PDSB

A translational study showcased at the 2025 @sitcancer Annual Meeting shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy. See key findings here: https://t.co/8kFQ7iiMtV #SITC25 $PDSB

PDS Biotech today announced positive clinical and translational data presented at the @sitcancer Annual Meeting. The presentations highlight immune-driven mechanisms and biomarkers that explain strong clinical activity of PDS0101 and PDS01ADC. https://t.co/8kFQ7iiMtV #SITC25

PDS Biotech today announced that the Company will host a conference call to report financial results for the quarter ended September 30, 2025 and provide a clinical programs update on Thursday, November 13th at 8:00 AM ET. To register, visit: https://t.co/nayPMvYbfd $PDSB

At the upcoming 2025 @sitcancer Annual Meeting, @TheNCI will highlight ongoing clinical and translational research across PDS Biotech's immunotherapy platforms in three abstracts, including one selected for a rapid oral abstract session. https://t.co/183Z5zdkKP #SITC2025 $PDSB

Frank Bedu-Addo, Ph.D., CEO of PDS Biotechnology, comments on new clinical and translational data to be presented at the 2025 SITC Annual Meeting on the Company's novel investigational cancer therapies, PDS0101 and PDS01ADC: https://t.co/183Z5zdkKP #SITC25

The FDA meeting request is based on final VERSATILE-002 results and a proposed amendment to VERSATILE-003 to reduce number of patients, while maintaining statistical power, and add PFS as an earlier primary endpoint for potential accelerated submission. https://t.co/LIVoL0aVQ9

Dr. Kirk Shepard, MD, Chief Medical Officer at PDS Biotech, highlights the Company’s efforts to shorten the time frame to make PDS0101 available to patients with HPV16-positive head and neck cancer: https://t.co/LIVoL0aVQ9 $PDSB